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Racial differences in antiretroviral treatment responses remain incompletely explained and may be a consequence of differential
pharmacokinetics (PK) associated with race. Raltegravir, an inhibitor of HIV-1 integrase, is commonly used in the treatment of
HIV-infected patients, many of whom are African-American. However, there are few data regarding the PK of raltegravir in Afri-
can-Americans. HIV-infected men and women, self-described as African-American and naive to antiretroviral therapy were
treated with raltegravir (RAL) at 400 mg twice a day, plus a fixed dose of tenofovir-emtricitabine (TDF/FTC) at 300 mg/200 mg
once daily. Intensive PK sampling was conducted over 24 h at week 4. Drug concentrations at two trough values of 12 and 24 h
after dosing (C12 and C24), area under the concentration-curve values (AUC), maximum drug concentration (Cmax), and the time
at which this concentration occurred (Tmax) in plasma were estimated with noncompartmental pharmacokinetic methods and
compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study,
a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients. A total of 38
African-American participants were enrolled (90% male) into the REAL cohort with the following median baseline charac-
teristics: age of 36 years, body mass index (BMI) of 23 kg/m2, and a CD4 cell count of 339/ml. Plasma HIV RNA levels were
below 200 copies/ml in 95% of participants at week 4. The characteristics of the 16 white QDMRK study participants were
similar, although fewer (69%) were male, the median age was higher (45 years), and BMI was lower (19 kg/m2). There was
considerable interindividual variability in RAL concentrations in both cohorts. Median C12 in REAL was 91 ng/ml (range,
10 to 1,386) and in QDMRK participants was 128 ng/ml (range, 15 to 1,074). The Cmax median concentration was 1,042
ng/ml (range, 196 to 10,092) for REAL and 1,360 ng/ml (range, 218 to 9,701) for QDMRK. There were no significant differ-
ences in any RAL PK parameter between these cohorts of African-American and white individuals. Based on plasma PK,
and with similar adherence rates, the performance of RAL among HIV-infected African-Americans should be no different
than that of infected patients who are white.
Racial differences in clinical responses to HIV therapy havebeen a consistent finding of both clinical trials and cohort
studies, with African-Americans having a greater risk for virologic
failure compared to other races (1–6). For example, in AIDS Clin-
ical Trials Group (ACTG) study A5202, a comparative trial of
efavirenz- and atazanavir/ritonavir-based initial treatment regi-
mens, African-American participants had a significantly shorter
time to virologic failure compared to white participants (7). Sim-
ilarly, the U.S. Department of Defense HIV Natural History Study
found that for HIV-infected African-Americans there was a 40%
lower odds of achieving undetectable HIV RNA levels compared
to whites, even after adjustment for multiple demographic, and
HIV disease- and treatment-related factors (2).
The relatively lower treatment response rates for African-
American HIV-infected patients remain poorly explained. Subop-
timal adherence to HIV therapy has been observed to be more
common among African-American study participants, but treat-
ment adherence alone does not fully account for racial differences
in treatment failure (8–12). There is limited information on
whether differential pharmacokinetics of antiretrovirals contrib-
utes to racial differences in treatment efficacy. A greater risk of
intolerance to efavirenz among African-Americans compared to
Hispanics and whites has been observed and an association be-
tween drug levels and polymorphisms of genes coding for drug
metabolism demonstrated (7, 12–15).
The HIV-1 integrase inhibitor raltegravir (RAL) is approved in
the United States for the treatment of HIV infection and, in com-
bination with tenofovir-emtricitabine (TDF/FTC), is listed as pre-
ferred for initial therapy of HIV-infected adults and adolescents
by the U.S. Department of Health and Human Services (DHHS)
(16). The pharmacological characteristics of RAL have been the
focus of study following observations of considerable intra- and
interindividual variability in the pharmacokinetic (PK) profile of
the drug and a nonlinear relationship between RAL plasma con-
centrations and antiretroviral effect (17–19). Although the high
variability in plasma concentrations of RAL relative to other anti-
retrovirals has complicated the modeling of RAL PK and thera-
peutic drug monitoring, the greater risk of treatment failure ob-
served with once daily compared to twice daily RAL regimens
suggests that drug exposure remains a critical determinant of the
efficacy of this agent (20).
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Whether there are racial differences in RAL PK among HIV-
infected persons is not known. Early-phase studies of RAL in HIV-
uninfected study volunteers found no effect of sex or race on RAL
PK (18), and the drug has been studied in infected populations
that are racially diverse (21, 22). However, there are limited data
regarding the PK, efficacy, and tolerability of RAL in African-
American HIV-infected individuals, despite the fact that a signif-
icant proportion of patients prescribed RAL in the United States is
African-American. We conducted a PK study to describe RAL PK
properties in antiretroviral naive, African-American, HIV-in-
fected patients.
(Preliminary data from were presented in part in July 2010 at
the XVIII International AIDS Conference, Vienna, Austria
[WEPE0103].)
MATERIALS AND METHODS
Study design and population. In this single-arm, open-label PK study,
HIV-infected individuals who self-identified as being African-American
were recruited and prescribed the antiretroviral combination of RAL at
400 mg twice daily orally plus a fixed dose of TDF/FTC at 300 mg/200 mg
once daily. In addition to being African-American, participants were re-
quired to have less than seven cumulative days of prior exposure to anti-
retroviral therapy, a plasma HIV RNA level of 1,000 copies/ml, an esti-
mated glomerular filtration rate by a modification of diet in renal disease
(MDRD) of at least 60 ml/min/1.73 m2, and hepatic transaminase levels
no more than three times the upper limit of normal to be eligible for study
entry. A genotypic resistance assay was performed as part of routine clin-
ical care and those with detected resistance to tenofovir or emtricitabine
were not enrolled.
Subjects were recruited at four HIV care clinics in North Carolina,
including the University of North Carolina Infectious Diseases Clinic in
Chapel Hill, the Wake Forest University Health Sciences Infectious Dis-
eases Clinic in Winston-Salem, the Durham County Early Intervention
Clinic in Durham, and the Wake County Early Intervention Clinic in
Raleigh. All subjects had to be able to provide informed consent. The
institutional review boards at UNC and Wake Forest Health Sciences
approved the study protocol.
Sample collection and processing. At 4 weeks after study treatment
was initiated, a PK visit was conducted, and blood samples were obtained
immediately prior to the next dose (time  0), and at 0.5, 1, 1.5, 2, 3, 4, 6,
8, and 12 h after an observed dose of RAL/TDF/FTC, as well as 4 and 12 h
after receiving a second dose at 12 h (16 and 24 h after the first dose).
Whole blood was obtained using EDTA-containing collection tubes (BD
Diagnostics, Franklin Lakes, NJ) and was centrifuged for 15 min at 4°C.
The resultant blood plasma (BP) was aliquoted into labeled cryovials and
stored at 80°C until analysis of RAL concentrations.
Routine chemistry and hematology laboratories, including serum cre-
atinine, hepatic transaminases, hemoglobin, and hematocrit, were also
drawn and processed at the UNC clinical laboratories.
On the day of the PK visit, a standardized breakfast (500 to 682 kcal, 23
to 25% calories from fat) was provided 30 min prior to the PK sampling,
and lunch was given after the 4-h blood draw. Participants were asked to
eat their meals within 30 min and to eat all of the food provided, if
possible. Grapefruit and grapefruit juice were not permitted in the meals
provided.
Analytical methods. RAL concentrations in BP were measured using
a validated and previously published HPLC/UV method (23). The dy-
namic range was 20 to 10,000 ng/ml, with a minimum of 90% accuracy,
and interday and intraday variabilities of 2.4 to 7.9% and 1.4 to 3.8%,
respectively.
PK parameters, including maximum concentration (Cmax), time to
maximal concentration (Tmax), the area under the time-concentration
curve over the 12-h dosing interval (AUC; measured in ng·h/ml), and the
trough concentrations (C12 and C24) were estimated using WinNonlin
Professional (version 5.2; Pharsight, Inc., Cary, NC). For PK analyses,
concentration measurements below the lower limit of detection were im-
puted as zero and those below the lower limit of quantitation (LLQ) were
imputed as 10 ng/ml (50% the LLQ).
Statistical methods. PK data from the 38 African American subjects
from the UNC study were compared to data generated in 16 white subjects
from the QDMRK study (Merck & Co.). Parameters included C12 and C24,
AUC, Cmax, and Tmax (20). Since only C12 data were available from the
QDMRK subjects, these values were used for comparisons to both the C12
and the C24 data from the UNC participants. To statistically assess
whether or not one study tended to have larger (or smaller) values for each
of these variables, a Wilcoxon rank-sum test was conducted for each of the
variables described.
RESULTS
Raltegravir PK in African-American patients with HIV infec-
tion. A total of 38 African-American participants underwent in-
tensive week 4 PK sampling. Most were middle-aged males (82%
male, median age of 36 years). The major characteristics of the
cohort participants are detailed in Table 1. Almost all (95%) had
suppressed HIV viremia (HIV RNA level  200 copies/ml) at
week 4, suggesting high levels of adherence.
The concentration-time profiles for each subject over 24 h,
with median/interquartile ranges, shown in Fig. 1 demonstrate
considerable interindividual variability in RAL levels. Summary
statistics of the PK parameters are listed in Table 2 and presented
graphically in Fig. 2.
Comparison to established raltegravir pharmacokinetic
data. To provide a context in which to interpret the PK data ob-
tained from the African-American patient cohort, these results
were compared to the data published in the RAL package insert
(18), as well as a subset of white participants of the QDMRK Trial
with available PK data (characteristics included in Table 1). The
mean RAL Cmax, Tmax, t1/2, and AUC0-12 reported in the RAL pack-
age insert were within the range seen in the African-American
subjects (Table 2). When comparing the data from the African-
American cohort participants and the white QDMRK partici-
pants, there were no statistically significant differences between
any of the PK variables (Fig. 2).
TABLE 1 Descriptive characteristics of participants in the REAL cohort





(n  16) Pa
Male (%) 89 69 0.11*
Median age (yr) 31.5 45 0.10
Median wt (kg) 81.2 72.8 0.06
Median BMI (kg/m2) 26 19 0.001
Median CD4 cell count at study entry
(cells/mm3)
338.5 342 0.48
Median HIV RNA at study entry
(copies/ml)
27,258 45,100 0.02
Median HIV RNA at PK study week
(copies/ml)b
39 39 0.86
HIV RNA level 200 copies per ml at
PK study week (%)
95 75 0.06†
a P values were obtained using Wilcoxon rank-sum tests unless otherwise noted. *, P
value obtained using the Fisher exact test.
b Values below lower limit of assay detection (40 copies/ml) are calculated as 39
copies/ml.
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DISCUSSION
RAL is a component of one of the four regimens preferred by the
U.S. DHHS antiretroviral guideline panel for initial therapy of
HIV, and given that 44% of the 48,000 individuals infected with
HIV each year are black/African-American, a substantial number
of African-Americans can be expected to be prescribed this anti-
retroviral (24). However, this is the first study, to our knowledge,
to examine the PK profile of RAL exclusively among African-
Americans.
As has been previously described in more racially heteroge-
neous cohorts, considerable variability in plasma concentrations
of RAL was observed (17–19). There is incomplete understanding
of the cause of the variability of RAL PK within and between
individuals. The human UDP glucuronosyltransferase isozyme
1A1 converts RAL to its the glucuronide metabolite and serves
as the major mechanism of clearance of the drug. However, RAL is
also subjected to renal excretion and variability in absorption, metab-
olism, and excretion may all contribute to the variability of RAL PK.
To place our findings in perspective, we explored whether the
PK profile derived from African-American participants differed
markedly from the PK data obtained in earlier studies of RAL.
Comparisons of the PK data from the present study to the sum-
mary PK data published in the RAL package insert (derived from
HIV-uninfected and infected volunteers) and the more detailed
data from 12-h intensive PK of white QDMRK participants revealed
no evidence of a significant effect of race on any PK parameter.
There are limitations to our study. Foremost among them,
comparisons were made to PK data from a cohort of white indi-
viduals who had been receiving therapy for 96 weeks, as opposed
to 4 weeks for the African-American UNC subjects. There can be
significant differences between individuals with short- and lon-
ger-term antiretroviral treatment in terms of viremia and inflam-
mation. However, given that the half-life of raltegravir is 9 h,
steady-state antiretroviral conditions should have been achieved
by 5 days of therapy and at both time points the vast majority of
subjects had suppressed viremia. Regardless, caution should be
exercised when interpreting this comparison, especially as the
sample size in each group is relatively small and PK properties can
be variable. In addition, the intracellular pharmacology of RAL
was not assessed here. There are several papers describing the in-
tracellular concentrations and activity of RAL, including those
measuring residence time of the drug on the integrase-DNA inte-
gration complex (19, 25). The intracellular partitioning ratio
relative to plasma has been reported as 11%, with no time-
related trends (26). The absence of any significant racial differ-
ence in plasma PK does not exclude the possibility of such a
difference in intracellular pharmacology of RAL, but with no
previous evidence of accumulation, excellent therapeutic re-
sponses in all populations, and no significant differences in
tolerability, this is unlikely.
Overall, the present study is the first to describe RAL PK among
a cohort of African-American HIV-infected individuals. Our find-
ings suggest that based on plasma PK, with similar adherence
rates, as evidenced by suppression of HIV replication, the perfor-
FIG 1 Individual subject concentration-time profiles over the 24-h study pe-
riod for African-American REAL cohort participants (n  38). RAL doses were
administered at 0 and 12 h. Boldface line indicates median concentration value
at each time point, with 25th and 75th percentile error bars. X indicates median
concentration reported in white QDMRK participants (n  16).
TABLE 2 Descriptive statistics overall for the REAL African-American cohort and white QDMRK participants
Study Variablea n Minimum 25th% Median Mean 75th% Maximum SD
REAL AUC 38 1,012 2,404 4,424 5,989 7,132 20,389 5,006
C12 38 10 47 91 190 219 1,386 268
C24 38 10 80 173 425 349 7,218 1,151
Cmax 38 196 532 1,042 1,799 1,686 10,092 2,075
Tmax 38 0.5 2.0 3.0 3.3 4.0 8.0 1.9
QDMRKb AUC 16 878 4,573 6,248 7,656 6,864 27,780 7,181
C12 16 15.3 51 128 239 302 1,074 283
C24 16 15.3 51 128 239 302 1,074 283
Cmax 16 218 760 1,360 2,105 2,219 9,701 2,373
Tmax 16 0.5 1.0 2.0 3.1 4.0 8.0 2.5




a Time (Tmax) is measured in hours, and concentrations (C12, C24, and Cmax) are measured in ng/ml.
b The values for C12 are used for C24 for the QDMRK data.
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mance of RAL among HIV-infected African-Americans should be
no different than that of infected patients who are white.
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